MiRNA-99a directly regulates AGO2 through translational repression in hepatocellular carcinoma

Oncogenesis

Volumn 3, Issue 4, 2014, Pages

  Zhang, J ^a   Jin, H ^a   Liu, H ^a,a   Iv, S ^a   Wang, B ^a   Wang, R ^a   Ding, M ^a   Yang, Y ^a   Li, L ^a   Fu, S ^a   Xie, D ^b   Wu, M ^a   Zhou, W ^a   Qian, Q ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Chinese Academy of Sciences   (China)

Author keywords

AGO2; Hepatocellular carcinoma; miR 99a; PTEN

Indexed keywords

ARGONAUTE 2 PROTEIN; MICRORNA; MICRORNA 99A; MICRORNA LET 7A; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER SURVIVAL; CANCER TISSUE; CARCINOGENICITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; TRANSLATION REGULATION; TUMOR DIFFERENTIATION; UPREGULATION;

EID: 84924285833     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2014.11     Document Type: Article

References (45)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
3. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6: 674-687.
4. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008; 48: 2047-2063.
5. Herranz H, Cohen SM. MicroRNAs and gene regulatory networks: managing the impact of noise in biological systems. Genes Dev 2010; 24: 1339-1344.
6. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
7. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866.
8. Huang S, He X. The role of microRNAs in liver cancer progression. Br J Cancer 2011; 104: 235-240.
9. Wang XW, Heegaard NH, Orum H. MicroRNAs in liver disease. Gastroenterology 2012; 142: 1431-1443.
10. Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 2011; 19: 232-243.
11. Connolly E, Melegari M, Landgraf P, Tchaikovskaya T, Tennant BC, Slagle BL et al. Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirusassociated hepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol 2008; 173: 856-864.
12. Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R et al. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 2009; 49: 1098-1112.
13. Petrelli A, Perra A, Schernhuber K, Cargnelutti M, Salvi A, Migliore C et al. Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression. Oncogene 2012; 31: 4517-4526.
14. Li D, Liu X, Lin L, Hou J, Li N, Wang C et al. MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem 2011; 286: 36677-36685.
15. Sun D, Lee YS, Malhotra A, Kim HK, Matecic M, Evans C et al. miR-99 family of microRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. Cancer Res 2011; 71: 1313-1324.
16. Chen Z, Jin Y, Yu D, Wang A, Mahjabeen I, Wang C et al. Down-regulation of the microRNA-99 family members in head and neck squamous cell carcinoma. Oral Oncol 2012; 48: 686-691.
17. Gu W, Fang S, Gao L, Tan Y, Yang Z. Clinic significance of microRNA-99a expression in human lung adenocarcinoma. J Surg Oncol 2013; 108: 248-255.
18. Kuo YZ, Tai YH, Lo HI, Chen YL, Cheng HC, Fang WY et al. MiR-99a exerts antimetastasis through inhibiting myotubularin-related protein 3 expression in oral cancer. Oral Dis 2014; 3: e65-75.
19. Cui L, Zhou H, Zhao H, Zhou Y, Xu R, Xu X et al. MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma. BMC Cancer 2012; 12: 546-556.
20. Lerman G, Avivi C, Mardoukh C, Barzilai A, Tessone A, Gradus B et al. MiRNA expression in psoriatic skin: reciprocal regulation of hsa-miR-99a and IGF-1R. PLoS ONE 2011; 6: e20916.
21. Mueller AC, Sun D, Dutta A. The miR-99 family regulates the DNA damage response through its target SNF2H. Oncogene 2013; 32: 1164-1172.
22. Schirle NT, MacRae IJ. The crystal structure of human Argonaute2. Science 2012; 336: 1037-1040.
23. Cenik ES, Zamore PD. Argonaute proteins. Curr Biol 2011; 21: R446-R449.
24. Cifuentes D, Xue H, Taylor DW, Patnode H, Mishima Y, Cheloufi S et al. A novel miRNA processing pathway independent of Dicer requires Argonaute2 catalytic activity. Science 2010; 328: 1694-1698.
25. Cheloufi S, Dos Santos CO, Chong MM, Hannon GJ. A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature 2010; 465: 584-589.
26. Morita S, Horii T, Kimura M, Goto Y, Ochiya T, Hatada I. One Argonaute family member, Eif2c2 (Ago2), is essential for development and appears not to be involved in DNA methylation. Genomics 2007; 89: 687-696.
27. Adams BD, Claffey KP, White BA. Argonaute-2 expression is regulated by epidermal growth factor receptor and mitogen-Activated protein kinase signaling and correlates with a transformed phenotype in breast cancer cells. Endocrinology 2009; 150: 14-23.
28. Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S et al. A MicroRNA targeting dicer for metastasis control. Cell 2010; 141: 1195-1207.
29. Kovaleva V, Mora R, Park YJ, Plass C, Chiramel AI, Bartenschlager R et al. miRNA-130a targets ATG2B and DICER1 to inhibit autophagy and trigger killing of chronic lymphocytic leukemia cells. Cancer Res 2012; 72: 1763-1772.
30. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007; 39: 673-677.
31. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 2008; 359: 2641-2650.
32. Lin RJ, Lin YC, Chen J, Kuo HH, Chen YY, Diccianni MB et al. microRNA signature and expression of Dicer and Drosha can predict prognosis and delineate risk groups in neuroblastoma. Cancer Res 2010; 70: 7841-7850.
33. Lin J, Horikawa Y, Tamboli P, Clague J, Wood CG, Wu X. Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma. Carcinogenesis 2010; 31: 1805-1812.
34. Faber C, Horst D, Hlubek F, Kirchner T. Overexpression of Dicer predicts poor survival in colorectal cancer. Eur J Cancer 2011; 47: 1414-1419.
35. Dedes KJ, Natrajan R, Lambros MB, Geyer FC, Lopez-Garcia MA, Savage K et al. Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. Eur J Cancer 2011; 47: 138-150.
36. Ravi A, Gurtan AM, Kumar MS, Bhutkar A, Chin C, Lu V et al. Proliferation and tumorigenesis of a murine sarcoma cell line in the absence of DICER1. Cancer Cell 2012; 21: 848-855.
37. Sekine S, Ogawa R, Ito R, Hiraoka N, McManus MT, Kanai Y et al. Disruption of Dicer1 induces dysregulated fetal gene expression and promotes hepatocarcinogenesis. Gastroenterology 2009; 136: 2304-2315.
38. Kitagawa N, Ojima H, Shirakihara T, Shimizu H, Kokubu A, Urushidate T et al. Downregulation of the microRNA biogenesis components and its association with poor prognosis in hepatocellular carcinoma. Cancer Sci 2013; 104: 543-551.
39. Cheng N, Li Y, Han ZG. Ago2 promotes tumor metastasis via upregulating FAK expression in hepatocellular carcinoma. Hepatology 2013; 57: 1906-1918.
40. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
41. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576.
42. Yuan SX, Yang F, Yang Y, Tao QF, Zhang J, Huang G et al. Long non-coding RNA-MVIH promotes angiogenesis and serves as a predictor for HCC patients' poor recurrence-free survival after hepatectomy. Hepatology 2012; 56: 2231-2241.
43. Jin H, Lv S, Yang J, Wang X, Hu H, Su C et al. Use of microRNA Let-7 to control the replication specificity of oncolytic adenovirus in hepatocellular carcinoma cells. PLoS ONE 2011; 6: e21307.
44. Szulc J, Wiznerowicz M, Sauvain MO, Trono D, Aebischer P. A versatile tool for conditional gene expression and knockdown. Nat Methods 2006; 3: 109-116.
45. Wang K, Liu J, Yan ZL, Li J, Shi LH, Cong WM et al. Overexpression of aspartyl-(asparaginyl)-beta-hydroxylase in hepatocellular carcinoma is associated with worse surgical outcome. Hepatology 2010; 52: 164-173.